Pixatimod

N/A

Report date: 2025/07/24 20:00:11
NME

Base Information

Drug NamePixatimod
Drug Alias NamePG-545PG500 program
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntercellular signaling peptides and proteins inhibitorsAngiogenesis inhibitorsHeparanase inhibitors
TargetsHeparanaseIntercellular signaling peptides and proteins
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesProgen Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAculeus Therapeutics Pty Ltd
Inactive CompaniesZucero Pty Ltd
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsMelanoma
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A